RAET1E

Across TCGA pan-cancer cohorts, RAET1E Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAET1E data layer compared with 24 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RAET1E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAET1E expression acts as an unfavorable survival marker.

BLCA, UCS, and SKCM are the cancer types where RAET1E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
SKCM	OS	Median	All	0.331	0.788	.002	6	view →
SARC	DFS	Median	All	0.127	0.611	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAET1E–BLCA (OS)

Open the BLCA breakdown →